

Mario Sznol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9162558/publications.pdf>

Version: 2024-02-01

84
papers

17,801
citations

87888

38
h-index

88630

70
g-index

89
all docs

89
docs citations

89
times ranked

24024
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	27.0	6,773
2	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. <i>Nature Genetics</i> , 2012, 44, 1006-1014.	21.4	1,052
3	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB <i>Clinical Oncology</i> , 2015, 33, 2004-2012.	1.6	1,035
4	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792.	1.6	930
5	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	30.7	900
6	Programmed death ligand-1 expression in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2014, 94, 107-116.	3.7	697
7	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 833-842.	1.6	517
8	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1021-1034.	7.0	458
9	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	1.6	385
10	Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.8	362
11	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. <i>Nature Genetics</i> , 2015, 47, 996-1002.	21.4	348
12	PLX4032, a selective BRAF ^{V600E} kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF ^{WT} melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 190-200.	3.3	315
13	Early B cell changes predict autoimmunity following combination immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 715-720.	8.2	298
14	Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy. <i>Diabetes Care</i> , 2015, 38, e55-e57.	8.6	278
15	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5461-5471.	7.0	234
16	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. <i>Clinical Cancer Research</i> , 2015, 21, 3052-3060.	7.0	198
17	Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5349-5357.	7.0	191
18	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 5191-5201.	7.0	181

#	ARTICLE	IF	CITATIONS
19	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R β -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 711-721.	9.4	180
20	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173.	9.4	158
21	Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1081-1088.	1.2	157
22	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	1.6	156
23	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 353-362.	30.7	132
24	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5869-5878.	7.0	131
25	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
26	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. <i>Nature Communications</i> , 2020, 11, 661.	12.8	124
27	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	7.0	117
28	KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. <i>Nature</i> , 2021, 598, 682-687.	27.8	117
29	Role of Chitinase 3-like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis. <i>Cancer Research</i> , 2015, 75, 487-496.	0.9	71
30	Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9018-9018.	1.6	70
31	Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9002-9002.	1.6	64
32	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
33	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. , 2019, 7, 196.		62
34	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	3.4	61
35	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 431-431.	1.6	59
36	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	1.6	55

#	ARTICLE	IF	CITATIONS
37	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3350-3358.	1.6	52
38	Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. , 2020, 8, e000341.		48
39	A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non—Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2021, 27, 4757-4767.	7.0	44
40	NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3006-3006.	1.6	44
41	Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2019, 37, 100-100.	1.6	44
42	Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. <i>Ophthalmology</i> , 2019, 126, 1058-1062.	5.2	43
43	Nuclear IRF-1 expression as a mechanism to assess —Capability— to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
44	Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4507-4507.	1.6	33
45	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2245-2261.	2.5	28
46	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	2.8	25
47	Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. , 2021, 9, e001506.		23
48	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3452-3463.	7.0	21
49	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175.	2.4	20
50	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	1.9	20
51	Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9012-9012.	1.6	20
52	Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2623-2623.	1.6	20
53	Resistance mechanisms to checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 47-55.	5.5	19
54	Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. <i>Nature Communications</i> , 2022, 13, 898.	12.8	19

#	ARTICLE	IF	CITATIONS
55	Release the Hounds! Activating the T-Cell Response to Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 374-375.	27.0	17
56	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). <i>Melanoma Research</i> , 2021, 31, 67-75.	1.2	15
57	A novel anti-melanoma SRC-family kinase inhibitor. <i>Oncotarget</i> , 2019, 10, 2237-2251.	1.8	13
58	Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. , 2015, 3, 10.		11
59	Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 495-501.	1.3	11
60	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4500-4500.	1.6	11
61	Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. <i>BMJ Open Ophthalmology</i> , 2022, 7, e000889.	1.6	10
62	Phase I Trial of Triapineâ€“Cisplatinâ€“Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers. <i>Frontiers in Oncology</i> , 2017, 7, 62.	2.8	8
63	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419.		8
64	389â€“...Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. , 2021, 9, A422-A422.		6
65	420â€“...Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. , 2020, , .		5
66	A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3094-3094.	1.6	5
67	Introducing a New Series: Immunotherapy Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 1773-1774.	7.0	4
68	Pharmacodynamic effect of IMCgp100 (TCRâ€“CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9523-9523.	1.6	4
69	Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 454-454.	1.6	3
70	Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCRâ€“anti-CD3, in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9530-9530.	1.6	3
71	CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9601-TPS9601.	1.6	3
72	Advances in the systemic treatment of metastatic melanoma. <i>Oncology</i> , 2013, 27, 374-81.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non-“small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, TPS9595-TPS9595.	1.6	3
74	Challenges in Conducting Clinical Research on Patients With Advanced Melanoma. Cancer Journal (Sudbury, Mass), 2017, 23, 75-78.	2.0	2
75	Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.. Journal of Clinical Oncology, 2019, 37, 9533-9533.	1.6	2
76	Phase Ib Study of Atezolizumab Plus Interferon-Î± with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology, 2021, 28, 5466-5479.	2.2	2
77	Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. , 2015, 3, .		1
78	Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.. Journal of Clinical Oncology, 2017, 35, 3-3.	1.6	1
79	Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNÎ² and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.. Journal of Clinical Oncology, 2020, 38, TPS3161-TPS3161.	1.6	1
80	Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).. Journal of Clinical Oncology, 2022, 40, 2560-2560.	1.6	1
81	TIL in Melanomaâ€”Similar Approaches, Different TIL Results, Unanswered Questions. Clinical Cancer Research, 2021, 27, 5156-5157.	7.0	0
82	A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision loss. Digital Journal of Ophthalmology: DJO, 2016, 22, 85.	0.6	0
83	A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10037-10037.	1.6	0
84	Clinical predictors of longer survival in patients with BRAF^{V600}-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.. Journal of Clinical Oncology, 2022, 40, 9555-9555.	1.6	0